Chemoprevention of Prostate Cancer by Naturally Occurring and Synthetic Organoselenium Compounds
Abstract
The lack of treatment for "worried well" patients with high-grade prostatic intraepithelial neoplasia (HGPIN) combined with issues of recurrence and hormone resistance in prostate cancer survivors remains a major public health obstacle. Consequently, there is a strong need for mechanism-based naturally occurring or synthetic agents that can inhibit the development and/or progression of prostate cancer. Epidemiologic and preclinical studies, as well as some clinical intervention trials, show an inhibitory role of selenium against prostate cancer. The organoselenium compounds SM and p-XSC differentially interfere with prostate cancer cell growth and androgen receptor signaling (androgen receptor protein expression, phosphorylation, and PSA gene expression) in human prostate cancer cells. We have shown, for the first time, that inhibition of androgen receptor signaling by these compounds may be due, in part, to modulation of the mammalian target of rapamycin (mTOR) pathway. Our findings support the concept that dose and form are critical for the anti-cancer properties of selenium compounds and that these agents may be of value, either individually or in combination with other therapies, for the treatment of prostate cancer because of their potential to inhibit critical prostate signaling pathways.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2009
- Accession Number
- ADA507009
Entities
People
- Nicole Facompre
Organizations
- Pennsylvania State University